Guangzhou Baiyunshan Pharmaceutical Holdings Ord Shs A (600332) Stock Price & News

600332:SHA

Guangzhou Baiyunshan Pharmaceutical Holdings Ord Shs A

CN¥19.94

+0.25%

(+0.050) 1D

Oct 16, 3:00:02 PM GMT+8 · CNY

All symbols

	Symbol	Price	Change	% Change

Generating top insights for 600332...

Open

CN¥19.89

High

CN¥20.19

Low

CN¥19.78

Mkt. cap

30.42B

Avg. vol.

5.87M

Volume

8.94M

Dividend

3.76%

Quarterly dividend

CN¥0.19

Ex-dividend date

Sep 10, 2026

P/E ratio

11.01

52-wk high

CN¥27.50

52-wk low

CN¥19.30

EPS

CN¥1.81

Shares outstanding

1.41B

No. of employees

26K

Open

CN¥19.89

High

CN¥20.19

Low

CN¥19.78

Mkt. cap

30.42B

Avg. vol.

5.87M

Volume

8.94M

Dividend

3.76%

Quarterly dividend

CN¥0.19

Ex-dividend date

Sep 10, 2026

P/E ratio

11.01

52-wk high

CN¥27.50

52-wk low

CN¥19.30

EPS

CN¥1.81

Shares outstanding

1.41B

No. of employees

26K

Related stocks

601607

Shanghai Pharmaceuticals Holding Ord Shs A

CN¥16.61

-0.89%

600196

Shanghai Fosun Pharmaceutical (Group) Ord Shs A

CN¥22.98

-0.91%

000513

Livzon Pharmaceutical Group Inc

CN¥27.95

-0.29%

002821

Asymchem Laboratories (Tianjin) Co Ltd

CN¥149.10

-6.17%

News stories

From web sources and news partners

marketscreener.com

7 minutes ago

S&P 500 subdued as gains in banks offset AI jitters; Dow at one-month high

Bloomberg.com

56 minutes ago

S&P 500 Steady as Warsh Boosts Expectations of Rate Hold

TradingView

1 hour ago

The Dow Jones Index Opens 0.48% Higher

Yahoo Finance

2 hours ago

S&P 500 Bull Market Has Reasons For Optimism, Says Baird — But Higher Rates Could Favor Quality Stocks

About Guangzhou Baiyunshan Pharmaceutical Holdings Ord Shs A

CEO-

Employees26.4K

FoundedSep 1, 1997

Headquarters-

SectorHealth care provider

Websitegybys.com.cn

All values in CNY	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	19.77B	16.05B	23.28B	18.81B
Cost of goods sold	16.58B	14.37B	18.55B	16.29B
Cost of revenue	16.58B	14.37B	18.55B	16.29B
Research and development expenses	158.44M	217.91M	158.68M	184.69M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.88B	2.21B	2.22B	1.83B
Operating expense	2.05B	2.50B	2.55B	2.11B
Total operating expenses	18.63B	16.87B	21.10B	18.40B
Operating income	1.14B	-820.04M	2.18B	409.74M
Other non operating income	83.07M	-100.40M	-1.28M	-15.15M
EBT including unusual items	1.09B	-494.18M	2.21B	393.99M
EBT excluding unusual items	1.24B	-825.17M	2.21B	377.21M
Income tax expense	271.49M	-156.77M	383.93M	59.00M
Effective tax rate	24.82%	31.72%	17.39%	14.97%
Other operating expenses	-46.93M	164.17M	91.90M	62.67M
Net income	793.91M	-326.94M	1.78B	312.16M
Net profit margin	4.02%	-2.04%	7.66%	1.66%
Earnings per share	-	-	-	-
Interest and investment income	117.54M	187.01M	140.88M	97.52M
Interest expense	-101.91M	-95.60M	-103.44M	-110.76M
Net interest expenses	15.64M	91.41M	37.44M	-13.24M
Depreciation and amortization charges	-	-	-	-
EBITDA	1.29B	-660.36M	2.34B	583.55M
Gain or loss from assets sale	3.63M	-107.74M	-	-938.61K

Ask anything